Reviewing Stryker Corporation (SYK) & Glaukos Corporation (GKOS)

Stryker Corporation (NYSE: SYK) and Glaukos Corporation (NYSE:GKOS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Risk & Volatility

Stryker Corporation has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Glaukos Corporation has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.

This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/reviewing-stryker-corporation-syk-glaukos-corporation-gkos/1654532.html

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Stryker Corporation and Glaukos Corporation, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stryker Corporation 2 7 11 0 2.45
Glaukos Corporation 0 0 7 0 3.00

Stryker Corporation presently has a consensus target price of $145.31, indicating a potential upside of 1.58%. Glaukos Corporation has a consensus target price of $51.33, indicating a potential upside of 57.80%. Given Glaukos Corporation’s stronger consensus rating and higher possible upside, analysts plainly believe Glaukos Corporation is more favorable than Stryker Corporation.

Valuation & Earnings

This table compares Stryker Corporation and Glaukos Corporation’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Stryker Corporation $11.96 billion 4.47 $3.29 billion $4.48 31.93
Glaukos Corporation $139.94 million 8.00 $8.15 million ($0.05) -650.60

Stryker Corporation has higher revenue and earnings than Glaukos Corporation. Glaukos Corporation is trading at a lower price-to-earnings ratio than Stryker Corporation, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

74.1% of Stryker Corporation shares are owned by institutional investors. 7.4% of Stryker Corporation shares are owned by company insiders. Comparatively, 16.4% of Glaukos Corporation shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Stryker Corporation and Glaukos Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Stryker Corporation 14.22% 24.26% 11.36%
Glaukos Corporation -0.81% 3.52% 3.06%

Dividends

Stryker Corporation pays an annual dividend of $1.70 per share and has a dividend yield of 1.2%. Glaukos Corporation does not pay a dividend. Stryker Corporation pays out 37.9% of its earnings in the form of a dividend. Glaukos Corporation has raised its dividend for 6 consecutive years.

Summary

Stryker Corporation beats Glaukos Corporation on 9 of the 16 factors compared between the two stocks.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company’s products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Bco Com Portugues  Given Consensus Rating of “Sell” by Analysts
Bco Com Portugues Given Consensus Rating of “Sell” by Analysts
GSA Capital Partners LLP Invests $258,000 in Aerie Pharmaceuticals, Inc.  Stock
GSA Capital Partners LLP Invests $258,000 in Aerie Pharmaceuticals, Inc. Stock
Crestwood Equity Partners LP  Shares Sold by GSA Capital Partners LLP
Crestwood Equity Partners LP Shares Sold by GSA Capital Partners LLP
GSA Capital Partners LLP Invests $270,000 in Sabra Healthcare REIT, Inc.  Stock
GSA Capital Partners LLP Invests $270,000 in Sabra Healthcare REIT, Inc. Stock
Citigroup Inc. Buys 897 Shares of WisdomTree Internationl Dvdnd Ex Fncl Fd
Citigroup Inc. Buys 897 Shares of WisdomTree Internationl Dvdnd Ex Fncl Fd
First Bancorp  Shares Sold by GSA Capital Partners LLP
First Bancorp Shares Sold by GSA Capital Partners LLP


Leave a Reply

 
© 2006-2017 Zolmax.